Literature DB >> 8419396

Inhibitory effects of a bacteria-derived sulfated polysaccharide against basic fibroblast growth factor-induced endothelial cell growth and chemotaxis.

Y Nakayama1, M Iwahana, N Sakamoto, N G Tanaka, Y Osada.   

Abstract

The effects of sulfated polysaccharides on the growth and chemotaxis of endothelial cells promoted by basic fibroblast growth factor (bFGF), a heparin-binding growth factor, and epidermal growth factor (EGF), a non-heparin-binding growth factor, were examined. The binding abilities of these two growth factors to D-gluco-D-galactan sulfate (DS-4152) were the same as to heparin. DS-4152 inhibited the growth and chemotaxis of the cells stimulated by bFGF, and prevented the binding of bFGF to the cells at both its low and high affinity binding sites: the former and the latter are heparin-like molecules and receptor proteins for bFGF, respectively. However, DS-4152 affected neither the binding of EGF to endothelial cells nor the proliferation and chemotaxis of the cells stimulated by the factor. Heparin also inhibited the binding of bFGF to low affinity binding sites to the same degree as DS-4152, but had little effect on the binding of bFGF to high affinity sites and no effects on bFGF-induced endothelial cell growth. Chondroitin sulfate A prevented neither the binding of bFGF to both sites of the cells nor bFGF-induced cell proliferation. We thus concluded that the inhibitory effects of DS-4152 against the growth and chemotaxis of endothelial cells induced by bFGF might be due to the prevention of bFGF binding to its receptor proteins resulting from the binding of DS-4152 to bFGF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419396     DOI: 10.1002/jcp.1041540102

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.

Authors:  Hui-Min Zhou; Fan Liu; Ai-Ge Yang; Yu-Qing Guo; Ya-Ru Zhou; Yong-Quan Gu; Bao-Yong Yan; Quan-Hai Li
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

Review 2.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

4.  Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.

Authors:  D Coltrini; M Rusnati; G Zoppetti; P Oreste; G Grazioli; A Naggi; M Presta
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

5.  Antitumor activity of FCE 26644 a new growth-factor complexing molecule.

Authors:  F Sola; M Farao; E Pesenti; A Marsiglio; N Mongelli; M Grandi
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice.

Authors:  P J Browning; D D Roberts; V Zabrenetzky; J Bryant; M Kaplan; R H Washington; A Panet; R C Gallo; T Vogel
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.